Liraglutide
Liraglutide is a medication that mimics a natural fullness hormone (GLP-1) in the body. It is FDA-approved as Victoza for type 2 diabetes and Saxenda for weight management, with an extensive record of clinical safety and effectiveness data.
Verified sources for Liraglutide
These vendors are vetted by PeptideWiki for purity testing and COA transparency.
Overview of Liraglutide
Activates GLP-1 receptors to enhance insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite through central mechanisms.
Central GLP-1 receptor activation in hypothalamus and brainstem, reducing hunger and increasing satiety signals.
Enhances insulin secretion from pancreatic beta cells only when glucose is elevated, minimizing hypoglycemia risk.
Reduces inappropriate glucagon secretion from alpha cells, lowering hepatic glucose production.
Slows food passage through stomach, prolonging digestion and promoting fullness.
LEADER trial demonstrated cardiovascular risk reduction in type 2 diabetes patients, with proven cardiovascular benefits
Read Full Liraglutide Dosage Guide
Research-backed dosing protocols, timing, and administration details
Browse more in this category
Metabolic & Weight Loss
Peptides for Weight Loss: Semaglutide, Tirzepatide, and the GLP-1 Revolution
GLP-1 peptides like semaglutide and tirzepatide have transformed weight loss treatment. Here's how they work, how they compare, what the clinical data shows, and what's coming next.
The Science of GLP-1 Agonists: Beyond Weight Loss
A deep dive into how GLP-1 receptor agonists like semaglutide and tirzepatide work at the molecular level — from brain signaling and gastric emptying to cardiovascular protection, neuroprotection, and the latest clinical trial data.